How is Arymo ER formulated to be abuse deterrent?
Arymo ER (morphine sulfate) tablets are formulated with Egalet's proprietary Guardian™ Technology to a create a physical and chemical barrier to prevent abuse.
Arymo ER has been discontinued and is no longer available for use.
What is Arymo ER?
Arymo ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Arymo ER is formulated as extended-release tablets. It is a Schedule II controlled substance with a high potential for abuse and and dependence.
How is Arymo ER Abuse-Deterrent?
Arymo ER tablets are designed to be difficult to manipulate for the purpose of misuse and abuse.
The Guardian™ Technology is a polymer matrix tablet technology that utilizes a novel application of the manufacturing process of injection molding, which results in tablets that are physically hard and difficult to manipulate. Arymo ER tablets have increased resistance to cutting, crushing, grinding or breaking compared to non-abuse-deterrent morphine sulfate extended-release tablets.
The tablets are also resistant to chemical manipulation making abuse via injection difficult, as contact with liquid results in a viscous hydrogel that is difficult to transfer into a syringe.
Related medical questions
- Which drugs cause opioid-induced constipation?
- Which painkiller should you use?
- How does fentanyl compare to heroin or other opiates?
- Treating Opioid Overdose with Naloxone
- How far back does a hair follicle test detect drugs?
- Does Vyvanse (lisdexamfetamine) show up on a drug test?
- Why is fentanyl so dangerous?
- What are the symptoms of a fentanyl overdose?
- Fentanyl test strips: where to get & how to use?
- How long does Fentanyl stay in your system?
- Is Vyvanse a controlled substance / narcotic drug?
- Arymo ER Information for Consumers
- Arymo ER prescribing info & package insert (for Health Professionals)
- Side Effects of Arymo ER (detailed)